Company Announcement / Press release Archives - Page 6 of 18

Xspray Pharma Partners with EVERSANA for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)

Xspray Pharma AB, (NASDAQ Stockholm: XSPRAY) has signed an agreement with EVERSANA® to support the U.S. launch and commercialization of the company’s first innovative cancer therapy Dasynoc for the treatment of chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL). While maintaining financial and strategic control, Xspray Pharma will grant EVERSANA exclusive commercialization access to […]

Interim Report Fourth Quarter 2022

October–December 2022, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -55,220 thousand (-51,944) Earnings per share before dilution amounted to -2.48 SEK (-2.62) Cash flow from operating activities amounted to SEK -35,003 thousand (-10,280) Cash flow from investing activities amounted to SEK -29,481 thousand (-33,691) January–December 2022, Group […]

Xspray presents novel scientific data for XS004 in the Chronic Myeloid Leukemia (CML) session at the 2022 Meeting of the American Society of Hematology

Xspray Pharma AB (NASDAQ Stockholm: XSPRAY), a biopharmaceutical company focused on developing high performing, amorphous forms of tyrosine kinase inhibitors (TKIs), has presented two posters examining the pharmacokinetics of XS004-dasatinib in healthy volunteers at the 64th Annual Meeting of the American Society of Hematology (ASH), December 10-13 in New Orleans, USA. “The treatment of CML […]

Xspray Pharma’s drug candidate XS004 granted orphan drug designation in the US for the treatment of acute lymphoblastic leukemia

Xspray Pharma (Nasdaq Stockholm: Xspray) has today received a decision from the US Food and Drug Administration (FDA) granting drug candidate XS004 (dasatinib) Orphan Drug Designation (ODD) for the treatment of acute lymphoblastic leukemia (ALL). The FDA decision is based on the potential that XS004 may be clinically superior to other drugs already approved for […]

Interim Report Third Quarter 2022

Once again an eventful quarter July–September 2022, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -28,651 thousand (-13,890) Earnings per share before dilution amounted to SEK -1.39 (-0.73) Cash flow from operating activities amounted to SEK -23,091 thousand (-16,524) Cash flow from investing activities amounted to SEK -29,126 […]

Xspray Announces 2 Poster Presentations for XS004 in Chronic Myeloid Leukemia (CML) at the American Society of Hematology (ASH) 2022 Annual Meeting

Xspray Pharma AB (NASDAQ Stockholm: XSPRAY), a biopharmaceutical company focused on developing improved, amorphous forms of TKIs, announces two poster presentations of data for XS004 in patients with chronic myeloid leukemia (CML) at the 64th annual American Society of Hematology (ASH) meeting December 10-13 in New Orleans, USA. “As patients live longer with hematologic malignancies, […]

Number of shares and votes in Xspray Pharma

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the number of shares and votes in Xspray Pharma AB has changed as a result of shares being registered due to the directed share issue which was carried out in October 2022. Through the direct share issue, carried out in October 2022, the number of outstanding […]

Xspray Pharma’s Nomination Committee for the Annual General Meeting 2023

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) publishes the Nomination Committee’s composition for the Annual General Meeting in 2023. The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting on 19 May 2022, consists of: Thomas Eldered, appointed by Flerie Invest AB Johan Gyllenswärd, appointed by Ribbskottet AB […]

Xspray Pharma has carried out a directed share issue raising proceeds of MSEK 100

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR OTHER MEASURES. Xspray Pharma AB (publ) (“Xspray” or the “Company”) has, based on […]

Interim Report Second Quarter 2022

A vision to improve patients’ lives Second quarter 2022 (April–June), Group· Net sales amounted to SEK 0 thousand (0)· Loss before tax amounted to SEK -28,865 thousand (-16,952)· Earnings per share before dilution amounted to SEK -1.40 (-0.89)· Cash flow from operating activities amounted to SEK -24,472 thousand (-12,831)· Cash flow from investing activities amounted to SEK -29,197 […]